Five years after coming to Seattle via its purchase of ZymoGenetics, drug giant Bristol-Myers Squibb is moving 40 Seattle-based research and development jobs to San Francisco, the company announced today. The manufacturing arm will remain in Seattle.
Bristol-Myers Squibb is expanding its California “Discovery hub” with the relocated jobs and newly-rented office space. The San Francisco-based researchers focus on cancer immunotherapies. The company is also concentrating a number of East Coast jobs at its Cambridge, Massachusetts hub.
The remaining 120 manufacturing jobs in Seattle will focus on early manufacturing for toxicology and clinical trials, according to the Seattle Times. Bristol-Myers Squibb bought ZymoGenetics in 2010, vowing to keep a presence in the South Lake Union area.
“In addition to investments in central New Jersey, our new location in Cambridge and our expanding presence in the San Francisco Bay area positions the company and our scientists in the heart of vibrant ecosystems of world class science, innovation and business opportunities, which offer ideal environments for fostering external collaboration,” said Francis Cuss, executive vice president and chief scientific officer at Bristol-Myers Squibb. “Ultimately, our goal is to continue to accelerate the translation of scientific knowledge and insights into the next wave of potentially transformational medicines for patients with serious diseases.”